Dutogliptin tartrate  (Synonyms: PHX-1149)

Dutogliptin tartrate (PHX-1149) is an orally available, potent, and selective dipeptidyl peptidase-4 (DPP4) inhibitor for the treatment of type 2 diabetes mellitus.

DPP4^[1]

Dutogliptin exhibits low plasma protein binding (11%) and is rapidly absorbed with a T_max of 3-4 h and a half-life of 10-13 h. Dutogliptin is metabolically stable and does not inhibit or induce the activity of major CYP450s^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

391.18

C₁₄H₂₆BN₃O₉

890402-81-0

O=C(CN[C@@H]1CCNC1)N(CCC2)[C@@H]2B(O)O.O[C@H]([C@H](C(O)=O)O)C(O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Marier JF, et al. Population pharmacokinetic analysis of dutogliptin, a selective dipeptidyl peptidase-4 inhibitor. Clin Pharmacol Drug Dev. 2014 Jul;3(4):297-304.  [Content Brief]

  [2]. Pattzi HM, et al. Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55.  [Content Brief]